(12) **Translation of European patent specification**

(11) **NO/EP 3512850 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 471/04 (2006.01)
A61P 35/00 (2006.01)
C07D 487/04 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.08.21
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.04.12
(86)	European Application Nr.	17772585.0
(86)	European Filing Date	2017.09.15
(87)	The European Application's Publication Date	2019.07.24
(30)	Priority	2016.09.16, US, 201662395618 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Vitae Pharmaceuticals, LLC, 5 Giralda Farms, Madison, NJ 07940, USA
(72)	Inventor	CACATIAN, Salvacion, 169 Front Street, Conshohocken, Pennsylvania 19428, USA CLAREMON, David A., 1508 Aidenn Lair Road, Maple Glen, Pennsylvania 19002, USA DONG, Chengguo, 96 Arthur Avenue, Staten Island, New York 10305, USA FAN, Yi, 40 Bittersweet Drive, Doylestown, Pennsylvania 18901, USA JIA, Lanqi, 22 Beaver Hill Road, Horsham, Pennsylvania 19044, USA LOTESTA, Stephen D., 99 Jennifer Lane, Burlington, New Jersey 08016, USA SINGH, Suresh B., 4 Adams Road, Kendall Park, New Jersey 08824, USA VENKATRAMAN, Shankar, 114 Country Lane, Lansdale, Pennsylvania 19446, USA YUAN, Jing, 537 Candlemaker Way, Lansdale, Pennsylvania 19446, USA ZHENG, Yajun, 712 Marlin Ave 3, Foster City California 94404, USA ZHUANG, Linghang, 3135 Fox Drive, Chalfont, Pennsylvania 18914, USA
(74)	Agent or Attorney	RWS, Europa House, Chiltern Park, Chiltern Hill, SL99FG CHALFONT ST PETER, Storbritannia

(54) Title **INHIBITORS OF THE MENIN-MLL INTERACTION**

(56) References Cited:

WO-A1-2015/058084
US-A1- 2010 144 758
WO-A2-2011/113798

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Forbindelse av formel I:



I

eller et farmasøytisk akseptabelt salt derav, hvori:

ring A er en C_{6-10}arylgruppe, 5–14-leddet heteroarylgruppe, C_{3-14}sykloalkylgruppe eller 4–14-leddet heterosykloalkylgruppe;

U er N eller CR^U, hvori R^U er H, halogen, CN, OH, C_{1-4}alkyl, C_{1-4}alkoksy, amino, C_{1-4}alkylamino eller C_{2-8}dialkylamino;

delen



er valgt fra:



, og



,

hvori R^Y er H, halogen, CN, OH, C_{1-4}alkyl, C_{1-4}alkoksy, amino, C_{1-4}alkylamino eller C_{2-8}dialkylamino;

X er F eller Cl;

L er valgt fra -C_{1-6}alkylen- og -(C_{1-4}alkylen)$_a$-Q-(C_{1-4}alkylen)$_b$-, hvori C_{1-6}alkylengruppen og en hvilken som helst C_{1-4}alkylengruppe av -(C_{1-4}alkylen)$_a$-Q-(C_{1-4}alkylen)$_b$-gruppen er eventuelt substituert med 1, 2 eller 3 substituenter uavhengig valgt fra halogen, CN, OH, C_{1-3}alkyl, C_{1-3}alkoksy, C_{1-3}hydroksyalkyl, C_{1-3}halogenalkyl, C_{1-3}halogenalkoksy, amino, C_{1-3}alkylamino og di(C_{1-3}alkyl)amino;

Q er -O-, -S-, -S(=O)-, -S(=O)$_2$-, -C(=O)-, -C(=O)NR^{q1}-, -C(=O)O-, -OC(=O)NR^{q1}-, -NR^{q1}-, -NR^{q1}C(=O)O-, -NR^{q1}C(=O)NR^{q1}-, -S(=O)$_2$NR^{q1}-, -C(=NR^{q2})- eller -C(=NR^{q2})-NR^{q1}-, hvori hver R^{q1} er uavhengig valgt fra H, C$_{1-6}$alkyl og C$_{1-3}$hydroksyalkyl, og hvori hver R^{q2} er uavhengig valgt fra H, C$_{1-6}$alkyl og CN;

Cy er en bindende C$_{6-14}$aryl-, bindende C$_{3-18}$sykloalkyl-, bindende 5–16-leddet heteroaryl-, eller bindende 4–18-leddet heterosykloalkylgruppe, hver av disse er eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra R^{Cy};

hver R^{Cy} er uavhengig valgt fra halogen, C$_{1-6}$alkyl, C$_{1-4}$halogenalkyl, C$_{1-4}$cyanoalkyl, C$_{2-6}$alkenyl, C$_{2-6}$alkynyl, C$_{6-10}$aryl, C$_{3-10}$sykloalkyl, 5–10-leddet heteroaryl, 4–10-leddet heterosykloalkyl, CN, NO$_2$, OR^{a1}, SR^{a1}, C(O)R^{b1}, C(O)NR^{c1}R^{d1}, C(O)OR^{a1}, OC(O)R^{b1}, OC(O)NR^{c1}R^{d1}, C(=NR^{e1})NR^{c1}R^{d1}, NR^{c1}C(=NR^{e1})NR^{c1}R^{d1}, NR^{c1}R^{d1}, NR^{c1}C(O)R^{b1}, NR^{c1}C(O)OR^{a1}, NR^{c1}C(O)NR^{c1}R^{d1}, NR^{c1}S(O)R^{b1}, NR^{c1}S(O)$_2$R^{b1}, NR^{c1}S(O)$_2$NR^{c1}R^{d1}, S(O)R^{b1}, S(O)NR^{c1}R^{d1}, S(O)$_2$R^{b1} og S(O)$_2$NR^{c1}R^{d1}, hvori C$_{1-6}$ alkylet, C$_{2-6}$alkenylet, C$_{2-6}$alkynylet, C$_{6-10}$arylet, C$_{3-10}$sykloalkylet, det 5–10-leddede heteroarylet, og det 4–10-leddede heterosykloalkylet er hver eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra CN, NO$_2$, OR^{a1}, SR^{a1}, C(O)R^{b1}, C(O)NR^{c1}R^{d1}, C(O)OR^{a1}, OC(O)R^{b1}, OC(O)NR^{c1}R^{d1}, C(=NR^{e1})NR^{c1}R^{d1}, NR^{c1}C(=NR^{e1})NR^{c1}R^{d1}, NR^{c1}R^{d1}, NR^{c1}C(O)R^{b1}, NR^{c1}C(O)OR^{a1}, NR^{c1}C(O)NR^{c1}R^{d1}, NR^{c1}S(O)R^{b1}, NR^{c1}S(O)$_2$R^{b1}, NR^{c1}S(O)$_2$NR^{c1}R^{d1}, S(O)R^{b1}, S(O)NR^{c1}R^{d1}, S(O)$_2$R^{b1} og S(O)$_2$NR^{c1}R^{d1};

R^1 er H, Cy^1, halogen, C$_{1-6}$alkyl, C$_{1-4}$halogenalkyl, C$_{1-4}$cyanoalkyl, C$_{2-6}$alkenyl, C$_{2-6}$alkynyl, CN, NO$_2$, OR^{a2}, SR^{a2}, C(O)R^{b2}, C(O)NR^{c2}R^{d2}, C(O)OR^{a2}, OC(O)R^{b2}, OC(O)NR^{c2}R^{d2}, C(=NR^{e2})NR^{c2}R^{d2}, NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}, NR^{c2}R^{d2}, NR^{c2}C(O)R^{b2}, NR^{c2}C(O)OR^{a2}, NR^{c2}C(O)NR^{c2}R^{d2}, NR^{c2}S(O)R^{b2}, NR^{c2}S(O)$_2$R^{b2}, NR^{c2}S(O)$_2$NR^{c2}R^{d2}, S(O)R^{b2}, S(O)NR^{c2}R^{d2}, S(O)$_2$R^{b2} og S(O)$_2$NR^{c2}R^{d2}, hvori C$_{1-6}$alkylet, C$_{2-6}$alkenylet og C$_{2-6}$alkynylet er hver eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra halogen, CN, NO$_2$, OR^{a2}, SR^{a2}, C(O)R^{b2}, C(O)NR^{c2}R^{d2}, C(O)OR^{a2}, OC(O)R^{b2}, OC(O)NR^{c2}R^{d2}, C(=NR^{e2})NR^{c2}R^{d2}, NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}, NR^{c2}R^{d2}, NR^{c2}C(O)R^{b2}, NR^{c2}C(O)OR^{a2}, NR^{c2}C(O)NR^{c2}R^{d2}, NR^{c2}S(O)R^{b2}, NR^{c2}S(O)$_2$R^{b2}, NR^{c2}S(O)$_2$NR^{c2}R^{d2}, S(O)R^{b2}, S(O)NR^{c2}R^{d2}, S(O)$_2$R^{b2} og S(O)$_2$NR^{c2}R^{d2};

Z er Cy^2, OR^{a3} eller C(O)NR^{c3}R^{d3}, hvori Cy^2 er eventuelt substituert med 1 eller 2 substituenter uavhengig valgt fra R^{Cy2};

hver R^2, R^3, R^4 og R^5 er uavhengig valgt fra H, halogen, C$_{1-6}$alkyl, C$_{1-4}$halogenalkyl, C$_{1-4}$cyanoalkyl, C$_{2-6}$alkenyl, C$_{2-6}$alkynyl, CN, NO$_2$, OR^{a4}, SR^{a4}, C(O)R^{b4}, C(O)NR^{c4}R^{d4}, C(O)OR^{a4}, OC(O)R^{b4}, OC(O)NR^{c4}R^{d4}, C(=NR^{e4})NR^{c4}R^{d4}, NR^{c4}C(=NR^{e4})NR^{c4}R^{d4}, NR^{c4}R^{d4}, NR^{c4}C(O)R^{b4}, NR^{c4}C(O)OR^{a4}, NR^{c4}C(O)NR^{c4}R^{d4}, NR^{c4}S(O)R^{b4}, NR^{c4}S(O)$_2$R^{b4}, NR^{c4}S(O)$_2$NR^{c4}R^{d4}, S(O)R^{b4}, S(O)NR^{c4}R^{d4}, S(O)$_2$R^{b4} og S(O)$_2$NR^{c4}R^{d4}, hvori C$_{1-6}$alkylet, C$_{2-6}$alkenylet og C$_{2-6}$alkynylet er hver eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra halogen, CN, NO$_2$, OR^{a4}, SR^{a4}, C(O)R^{b4}, C(O)NR^{c4}R^{d4}, C(O)OR^{a4}, OC(O)R^{b4}, OC(O)NR^{c4}R^{d4},

$C(=NR^{e4})NR^{c4}R^{d4}$, $NR^{c4}C(=NR^{e4})NR^{c4}R^{d4}$, $NR^{c4}R^{d4}$, $NR^{c4}C(O)R^{b4}$, $NR^{c4}C(O)OR^{a4}$, $NR^{c4}C(O)NR^{c4}R^{d4}$, $NR^{c4}S(O)R^{b4}$, $NR^{c4}S(O)_2R^{b4}$, $NR^{c4}S(O)_2NR^{c4}R^{d4}$, $S(O)R^{b4}$, $S(O)NR^{c4}R^{d4}$, $S(O)_2R^{b4}$ og $S(O)_2NR^{c4}R^{d4}$;

hver Cy^1 er uavhengig valgt fra C_{6-14}aryl, C_{3-18}sykloalkyl, 5–16-leddet heteroaryl, og 4–18-leddet heterosykloalkyl, hver av disse er eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra R^{Cy1};

hver Cy^2 er uavhengig valgt fra C_{6-14}aryl, C_{3-18}sykloalkyl, 5–16-leddet heteroaryl og 4–18-leddet heterosykloalkyl, hver av disse er eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra R^{Cy2};

hver R^{Cy1} og R^{Cy2} er uavhengig valgt fra halogen, C_{1-6}alkyl, C_{1-4}halogenalkyl, C_{1-4}cyanoalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, fenyl, C_{3-7}sykloalkyl, 5–6-leddet heteroaryl, og 4–7-leddet heterosykloalkyl, CN, NO_2, OR^{a5}, SR^{a5}, $C(O)R^{b5}$, $C(O)NR^{c5}R^{d5}$, $C(O)OR^{a5}$, $OC(O)R^{b5}$, $OC(O)NR^{c5}R^{d5}$, $C(=NR^{e5})NR^{c5}R^{d5}$, $NR^{c5}C(=NR^{e5})NR^{c5}R^{d5}$, $NR^{c5}R^{d5}$, $NR^{c5}C(O)R^{b5}$, $NR^{c5}C(O)OR^{a5}$, $NR^{c5}C(O)NR^{c5}R^{d5}$, $NR^{c5}S(O)R^{b5}$, $NR^{c5}S(O)_2R^{b5}$, $NR^{c5}S(O)_2NR^{c5}R^{d5}$, $S(O)R^{b5}$, $S(O)NR^{c5}R^{d5}$, $S(O)_2R^{b5}$ og $S(O)_2NR^{c5}R^{d5}$, hvori C_{1-6}alkylet, C_{2-6}alkenylet, C_{2-6}alkynylet, fenylet, C_{3-7}sykloalkylet, det 5–6-leddede heteroarylet, og det 4–7-leddede heterosykloalkylet er hver eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra CN, NO_2, OR^{a5}, SR^{a5}, $C(O)R^{b5}$, $C(O)NR^{c5}R^{d5}$, $C(O)OR^{a5}$, $OC(O)R^{b5}$, $OC(O)NR^{c5}R^{d5}$, $C(=NR^{e5})NR^{c5}R^{d5}$, $NR^{c5}C(=NR^{e5})NR^{c5}R^{d5}$, $NR^{c5}R^{d5}$, $NR^{c5}C(O)R^{b5}$, $NR^{c5}C(O)OR^{a5}$, $NR^{c5}C(O)NR^{c5}R^{d5}$, $NR^{c5}S(O)R^{b5}$, $NR^{c5}S(O)_2R^{b5}$, $NR^{c5}S(O)_2NR^{c5}R^{d5}$, $S(O)R^{b5}$, $S(O)NR^{c5}R^{d5}$, $S(O)_2R^{b5}$og $S(O)_2NR^{c5}R^{d5}$;

hver R^{a1}, R^{b1}, R^{c1}, R^{d1}, R^{a2}, R^{b2}, R^{c2}, R^{d2}, R^{a3}, R^{b3}, R^{c3}, R^{d3}, R^{a4}, R^{b4}, R^{c4}, R^{d4}, R^{a5}, R^{b5}, R^{c5} og R^{d5} er uavhengig valgt fra H, C_{1-6}alkyl, C_{1-4}halogenalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{3-10}sykloalkyl, 5–10-leddet heteroaryl, 4–10-leddet heterosykloalkyl, C_{6-10}aryl-C_{1-6}alkyl, C_{3-10}sykloalkyl-C_{1-6}alkyl, (5–10-leddet heteroaryl)-C_{1-6}alkyl, og (4–10-leddet heterosykloalkyl)-C_{1-6}alkyl, hvori C_{1-6}alkylet, C_{2-6}alkenylet, C_{2-6}alkynylet, C_{6-10}arylet, C_{3-10}sykloalkylet, det 5–10-leddede heteroarylet, det 4–10-leddede heterosykloalkylet, C_{6-10}aryl-C_{1-6}alkylet, C_{3-10}sykloalkyl-C_{1-6}alkylet, (det 5–10-leddede heteroaryl)-C_{1-6}alkylet og (det 4–10-leddede heterosykloalkyl)-C_{1-6}alkylet er hver eventuelt substituert med 1, 2, 3, 4 eller 5 substituenter uavhengig valgt fra Rg;

hver R^{e1}, R^{e2}, R^{e3}, R^{e4} og R^{e5} er uavhengig valgt fra H, C_{1-4}alkyl og CN;

hver R^g er uavhengig valgt fra gruppen som består av OH, NO_2, CN, halogen, C_{1-20}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-4}halogenalkyl, C_{1-6}alkoksy, C_{1-6}halogenalkoksy, cyano-C_{1-3}alkyl, HO-C_{1-3}alkyl, amino, C_{1-6}alkylamino, di(C_{1-6}alkyl)amino, tiol, C_{1-6}alkyltio, C_{1-6}alkylsulfinyl, C_{1-6}alkylsulfonyl, karboksy, C_{1-6}alkylkarbonyl og C_{1-6}alkoksykarbonyl;

n er 0 eller 1;

m er 0 eller 1;

p er 0, 1, 2 eller 3;

r er 0, 1 eller 2;

a er 0 eller 1; og

b er 0 eller 1,

hvori en hvilken som helst sykloalkyl- eller heterosykloalkylgruppe er eventuelt substituert med 1 eller 2 oksogrupper.

2. Forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, hvori m er 1.

3. Forbindelsen ifølge krav 1 eller 2, hvori

(a) U er N; eller

(b) U er CR^U.

4. Forbindelsen ifølge et hvilket som helst av kravene 1 til 3, eller et farmasøytisk akseptabelt salt derav, hvori;

(a) X er F; eller

(b) X er Cl.

5. Forbindelsen ifølge et hvilket som helst av kravene 1 til 4, eller et farmasøytisk akseptabelt salt derav, hvori:

(a) delen



er



;

(b) delen



er



;

(c) delen



er



;

(d) delen



er



;

eller

(e) delen



er



.

6. Forbindelsen ifølge et hvilket som helst av kravene 1 til 5, eller et farmasøytisk akseptabelt salt derav, hvori:

(a) ring A er en 5–10-leddet heteroarylgruppe, C_{3-10}sykloalkylgruppe eller en 4–10-leddet heterosykloalkylgruppe;

(b) ring A er en gruppe som har formelen:





eller ,

hvori e og f indikerer festepunkter til resten av molekylet; eller

(c) ring A er en gruppe som har formelen:



, , eller ,

hvori e og f indikerer festepunkter til resten av molekylet.

7. Forbindelsen ifølge et hvilket som helst av kravene 1 til 6, eller et farmasøytisk akseptabelt salt derav, hvori L er -C_{1-6}alkylen- eventuelt substituert med 1, 2 eller 3 substituenter uavhengig valgt fra halogen, CN, OH, C_{1-3}alkyl, C_{1-3}alkoksy, C_{1-3}halogenalkyl, C_{1-3}halogenalkoksy, amino, C_{1-3}alkylamino og di(C_{1-3}alkyl)amino; eventuelt hvori L er -C_{1-6}alkylen-; videre eventuelt metylen, etylen eller butylen;

eller hvori L er -(C_{1-4}alkylen)$_a$-Q-(C_{1-4}alkylen)$_b$-, hvori en hvilken som helst C_{1-4}alkylengruppe av -(C_{1-4}alkylen)$_a$-Q-(C_{1-4}alkylen)$_b$-gruppen er eventuelt substituert med 1, 2 eller 3 substituenter uavhengig valgt fra halogen, CN, OH, C_{1-3} alkyl, C_{1-3}alkoksy, C_{1-3}halogenalkyl, C_{1-3}halogenalkoksy, amino, C_{1-3}alkylamino og di(C_{1-3}alkyl)amino.

8. Forbindelsen ifølge et hvilket som helst av kravene 1 til 6, eller et farmasøytisk akseptabelt salt derav, hvori L er valgt fra -$NHCH_2$-, -$N(CH_3)CH_2$-, -O-, -C(O)- og -$C(O)CH_2$-.

9. Forbindelsen ifølge et hvilket som helst av kravene 1 til 8, eller et farmasøytisk akseptabelt salt derav, hvori Cy er:

(a) en bindende C_{6-10}aryl-, bindende C_{3-10}sykloalkyl-, bindende 5–10-leddet heteroaryl-, eller bindende 4–10-leddet heterosykloalkylgruppe, som hver er eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra R^{Cy};

(b) en bindende fenyl-, bindende C_{3-10}sykloalkyl-, bindende 5–10-leddet heteroaryl-, eller bindende 4–10-leddet heterosykloalkylgruppe, hver av disse er eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra R^{Cy};

(c) en bindende gruppe som har formelen:

 ,  ,  ,  ,

 ,  ,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  ,  eller

 ,

hver av disse er eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra R^{Cy}; eller

(d) en bindende gruppe som har formelen:

 ,  ,  eller  ,

hver av disse er eventuelt substituert med 1, 2, 3 eller 4 substituenter uavhengig valgt fra R^{Cy}.

10. Forbindelsen ifølge et hvilket som helst av kravene 1 til 9, eller et farmasøytisk akseptabelt salt derav, hvori:

(a) Z er $C(O)NR^{c3}R^{d3}$;

(b) Z er $C(O)NR^{c3}R^{d3}$, og R^{c3} og R^{d3} er uavhengig valgt fra H og C_{1-6}alkyl;

(c) Z er $C(O)NR^{c3}R^{d3}$, og R^{c3} og R^{d3} er begge C_{1-6}alkyl; eller

(d) Z er $C(O)NR^{c3}R^{d3}$, og R^{c3} og R^{d3} er uavhengig valgt fra metyl og isopropyl.

11. Forbindelsen ifølge et hvilket som helst av kravene 1 til 10, eller et farmasøytisk akseptabelt salt derav, hvori R^3 er H, og/eller R^4 er H.

12. Forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, som har (a) formel Ila, IIb, IIc, IId, IIe, IIIa, IIIb, IIIc eller IIId:



IIa



IIb



IIc



IId



IIe



IIIa



IIIb



IIIc



IIId



IIIe;

eller

(b) formel IVa, IVb, IVc, IVd, Va, Vb eller Vc:



IVa



IVb



IVc



IVd



Va



Vb



Vc.

13. Forbindelsen ifølge krav 1, hvori forbindelsen er valgt fra:

5-((7-(5-(4-fluor-2-(trifluormetyl)fenoksy)pyrimidin-4-yl)-2,7-diazaspiro[4.4]nonan-2-yl)metyl)-1H-benzo[d]imidazol-2(3H)-on;

2-(3-(1-((2-cyano-4-metyl-1H-indol-5-yl)metyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;

5-((7-(5-(2,4-diklorfenoksy)pyrimidin-4-yl)-2,7-diazaspiro[4.4]nonan-2-yl)metyl)-1H-benzo[d]imidazol-2(3H)-on;

5-fluor-N-isopropyl-N-metyl-2-(3-(1-((tetrahydro-2H-pyran-4-yl)metyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(1-(2-(tetrahydro-2H-pyran-4-yl)etyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

2-(3-(1-((2-cyano-1H-indol-5-yl)metyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;

2-(3-(1-((2-cyano-1H-indol-6-yl)metyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;

5-fluor-2-(3-(1-(4-fluorbenzyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;

2-(3-(1-(4-klorbenzyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(1-(4-(trifluormetyl)benzyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

2-(3-(1-(4-cyanobenzyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(1-(4-(metylsulfonyl)benzyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(1-(2-metylbenzyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
2-(3-(1-(2-klorbenzyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
2-(3-(1-((3,3-difluorsyklobutyl)metyl)piperidin-4-yl)- 1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-metylpiperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
tert-butyl-(trans-4-(2-(4-(1-(4-fluor-2-(isopropyl(metyl)karbamoyl)fenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)piperidin-1-yl)etyl)sykloheksyl)karbamat;
2-(3-(1-(2-(trans-4-acetamidosykloheksyl)etyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-(2-(trans-4-(metylsulfonamido)sykloheksyl)etyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
tert-butyl-(trans-4-((4-(1-(4-fluor-2-(isopropyl(metyl)karbamoyl)fenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)piperidin-1-yl)metyl)sykloheksyl)karbamat;
2-(3-(1-(1-(trans-4-acetamidosykloheksyl)metyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-((trans-4-(metylsulfonamido)sykloheksyl)metyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
2-(3-(1-(4-acetamidobenzyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-(4-(metylsulfonamido)benzyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-(4-(metylsulfonyl)fenetyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
2-(3-(1-(3-cyanofenetyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-(3-(metylkarbamoyl)fenetyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
trans-(5-fluor-2-(3-(1-((4-hydroksysykloheksyl)metyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid);
cis-(5-fluor-2-(3-(1-((4-hydroksysykloheksyl)metyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid);
5-fluor-N-isopropyl-N-metyl-2-(3-(1-(2-(1-(metylsulfonyl)piperidin-4-yl)etyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

2-(3-(1-(4-(2-cyanopropan-2-yl)fenetyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-(1-fenyletyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
2-(3-(2-benzylpiperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
2-(3-(1-benzylpiperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-etyl-5-fluor-N-isopropylbenzamid;
2-(3-(1-benzylpiperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N,N-diisopropylbenzamid;
N-(trans-4-(2-(4-(1-(2-(syklopropylmetoksy)-4-fluorfenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)piperidin-1-yl)etyl)sykloheksyl)metansulfonamid;
1-(2-(syklopropylmetoksy)-4-fluorfenyl)-3-(1-(4-fluorbenzyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin;
2-(3-(1-benzylpiperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-(2-hydroksyetyl)-N-isopropylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-(((1r,4r)-4-(metylsulfonamido)sykloheksyl)metyl)azepan-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
2-(3-(azepan-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-((4-(1-(4-fluor-2-isobutylfenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)piperidin-1-yl)metyl)-4-metyl-1H-indol-2-karbonitril;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-2-(3-(1-((1-(2-hydroksyetyl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
2-(3-(1-benzylpiperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
2-(3-(1-(sykloheksylmetyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
N-etyl-5-fluor-N-isopropyl-2-(3-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
(S)-N-etyl-5-fluor-N-isopropyl-2-(3-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
(R)-N-etyl-5-fluor-N-isopropyl-2-(3-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
N-etyl-5-fluor-2-(3-(1-((1-(2-hydroksyetyl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropylbenzamid;

(S)-N-etyl-S-fluor-2-(3-(1-((1-(2-hydroksyetyl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropylbenzamid;

(R)-N-etyl-5-fluor-2-(3-(1-((1-(2-hydroksyetyl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropylbenzamid;

2-(3-(2-azaspiro[3.5]nonan-7-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(2-metyl-2-azaspiro[3.5]nonan-7-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(2-metyl-1,2,3,4-tetrahydroisokinolin-6-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

5-fluor-2-(3-(4-hydroksysykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;

2-(3-(4-(dimetylamino)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(trans-4-(pyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(cis-4-(pyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

2-(3-(trans-4-aminosykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;

2-(3-(cis-4-aminosykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(4-fenoksysykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(4-(((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)amino)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

5-fluor-N-isopropyl-N-metyl-2-(3-(4-(((4-(metylsulfonamido)sykloheksyl)metyl)amino)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

2-(7-(1-((2-cyano-4-metyl-1H-indol-5-yl)metyl)piperidin-4-yl)-SH-pyrrolo[3,2-d]pyrimidin-5-yl)-5-fluor-N-isopropyl-N-metylbenzamid;

2-(7-(1-((2-cyano-4-metyl-1H-indol-5-yl)metyl)piperidin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)-5-fluor-N,N-dimetylbenzamid;

5-(4-fluorfenyl)-7-(1-((tetrahydro-2H-pyran-4-yl)metyl)piperidin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin;

5-((4-(5-(4-fluorfenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-4-metyl-1H-indol-2-karbonitril;
5-((4-(5-(4-fluorfenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-1H-benzo[d]imidazol-2(3H)-on;
7-(1-((1H-indol-6-yl)metyl)piperidin-4-yl)-5-(4-fluorfenyl)-SH-pyrrolo[3,2-d]pyrimidin;
7-(1-((1H-indol-5-yl)metyl)piperidin-4-yl)-5-(4-fluorfenyl)-SH-pyrrolo[3,2-d]pyrimidin;
5-((4-(5-(4-fluor-2-metylfenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-4-metyl-1H-indol-2-karbonitril;
5-((4-(5-(3-fluorfenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-4-metyl-1H-indol-2-karbonitril;
4-metyl-5-((4-(5-fenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-1H-indol-2-karbonitril;
5-((4-(5-fenyl-SH-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-1H-benzo[d]imidazol-2(3H)-on;
5-fluor-N-isopropyl-N-metyl-2-(1-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(1-(1-(2-((1r,4r)-4-(metylsulfonamido)sykloheksyl)etyl)piperidin-4-yl)-2-okso-1,2-dihydro-3H-imidazo[4,5-c]pyridin-3-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(2-okso-1-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-4-yl)-1,2-dihydro-3H-imidazo[4,5-c]pyridin-3-yl)benzamid;
5-((4-(3-(4-fluorfenyl)-2-okso-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)piperidin-1-yl)metyl)-4-metyl-1H-indol-2-karbonitril;
2-(1-(1-(sykloheksylmetyl)piperidin-4-yl)-2-okso-1,2-dihydro-3H-imidazo[4,5-c]pyridin-3-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
2-(1-(1-((2-cyano-4-metyl-1H-indol-5-yl)metyl)piperidin-4-yl)-2-okso-1,2-dihydro-3H-imidazo[4,5-c]pyridin-3-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-2-(1-(1-(4-fluorbenzyl)piperidin-4-yl)-2-okso-1,2-dihydro-3H-imidazo[4,5-c]pyridin-3-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(1-((1-(2-hydroksyetyl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N,N-diisopropylbenzamid;
5-fluor-N,N-diisopropyl-2-(3-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N,N-diisopropyl-2-(3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
(R)-2-(5-((3-(1-(4-fluor-2-(isopropyl(metyl)karbamoyl)fenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)piperidin-1-yl)metyl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-1-yl)etylacetat;
(R)-2-(5-((3-(1-(4-fluor-2-(isopropyl(metyl)karbamoyl)fenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)piperidin-1-yl)metyl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-1-yl)etylstearat;

5-fluor-N,N-diisopropyl-2-(3-(1-(((1r,4r)-4-(metylsulfonamido)sykloheksyl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
2-(3-(1-((3-cyano-3-metyl-2-oksoindolin-6-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(2-((trans-3-(metylsulfonamido)syklobutyl)metyl)oktahydrosyklopenta[c]pyrrol-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(2-((trans-4-(metylsulfonamido)sykloheksyl)metyl)oktahydrosyklopenta[c]pyrrol-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(2-((1-(metylsulfonyl)piperidin-4-yl)metyl)oktahydrosyklopenta[c]pyrrol-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-((cis-3-(metylsulfonamido)syklobutyl)metyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-(2-(4-(metylsulfonamido)piperidin-1-yl)etyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-(pyridin-2-yl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-2-(3-(4-(3-hydroksypyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(trans-4-((S)-2-(hydroksymetyl)pyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(cis-4-((S)-2-(hydroksymetyl)pyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(trans-4-(3-(hydroksymetyl)azetidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(cis-4-(3-(hydroksymetyl)azetidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(trans-4-((R)-2-(hydroksymetyl)pyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(cis-4-((R)-2-(hydroksymetyl)pyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(trans-4-((R)-3-(hydroksymetyl)pyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(cis-4-((R)-3-(hydroksymetyl)pyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;

5-fluor-2-(3-(trans-4-((S)-3-(hydroksymetyl)pyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(cis-4-((S)-3-(hydroksymetyl)pyrrolidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(trans-4-(piperidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(cis-4-(piperidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-2-(3-(trans-4-(4-hydroksypiperidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(cis-4-(4-hydroksypiperidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
2-(3-(trans-4-(4,4-difluorpiperidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
2-(3-(cis-4-(4,4-difluorpiperidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(trans-4-(3-hydroksypiperidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(cis-4-(3-hydroksypiperidin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(trans-4-(4-(2-hydroksyetyl)piperazin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-2-(3-(cis-4-(4-(2-hydroksyetyl)piperazin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(4-(3-oksopiperazin-1-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(trans-4-morfolinosykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(cis-4-morfolinosykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
1-(trans-4-(1-(4-fluor-2-(isopropyl(metyl) karbamoyl)fenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)sykloheksyl)piperidin-4-karboksylsyre;
1-(cis-4-(1-(4-fluor-2-(isopropyl(metyl) karbamoyl)fenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)sykloheksyl)piperidin-4-karboksylsyre;
5-((3-(1-(2-(3-syklopropyl-5-metyl-4H-1,2,4-triazol-4-yl)-4-fluorfenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)piperidin-1-yl)metyl)-1H-benzo[d]imidazol-2(3H)-on;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)pyrrolidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

5-fluor-2-(3-(1-((1-(2-hydroksyetyl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)pyrrolidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N-isopropyl-N-metylbenzamid;
N-metyl-5-fluor-N-isopropyl-2-(3-(1-((trans-4-(metylsulfonamido)sykloheksyl)metyl)pyrrolidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
N-etyl-5-fluor-N-isopropyl-2-(3-(1-((trans-4-(metylsulfonamido)sykloheksyl)metyl)pyrrolidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-2-(3-(1-((1-(2-hydroksyetyl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)pyrrolidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N,N-diisopropylbenzamid;
5-fluor-N,N-diisopropyl-2-(3-(1-((trans-4-(metylsulfonamido)sykloheksyl)metyl)pyrrolidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(4-(metyl((4-(metylsulfonamido)sykloheksyl)metyl)amino)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
2-(3-(trans-4-benzamidosykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
2-(3-(trans-4-(sykloheksankarboksamido)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
2-(3-(trans-4-benzamidosykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
2-(3-(1-(2,3-dihydro-1H-inden-2-karbonyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(1-(2-fenylacetyl)piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-2-(3-(1-((1-(2-hydroksyetyl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-N,N-diisopropylbenzamid;
5-fluor-N-isopropyl-N-metyl-2-(1-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-2-tiokso-1,2-dihydro-3H-imidazo[4,5-c]pyridin-3-yl)benzamid;
tert-butyl-((1r,4r)-4-(2-(3-(1-(2-(diisopropylkarbamoyl)-4-fluorfenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)azetidin-1-yl)etyl)sykloheksyl)karbamat;
5-fluor-N,N-diisopropyl-2-(3-(1-(2-((1r,4r)-4-(metylsulfonamido)sykloheksyl)etyl)azetidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N,N-diisopropyl-2-(3-(1-(((1r,4r)-4-(metylsulfonamido)sykloheksyl)metyl)azetidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;

5-fluor-N,N-diisopropyl-2-(3-(4-(2-(metylsulfonamido)-6-azaspiro[3.4]oktan-6-yl)sykloheksyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N,N-diisopropyl-2-(3-(1-((2-okso-2,3-dihydrobenzo[d]oksazol-5-yl)metyl)pyrrolidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
eller et farmasøytisk akseptabelt salt derav.

14. Forbindelse valgt fra gruppen som består av:
5-fluor-N-isopropyl-N-metyl-2-(3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
2-(3-((2S,6R)-2,6-dimetylpiperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-fluor-N-isopropyl-N-metylbenzamid;
5-fluor-N,N-diisopropyl-2-(3-(piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-fluor-N-isopropyl-N-metyl-2-(3-(oktahydrosyklopenta[c]pyrrol-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid;
5-((4-(1-(4-fluorfenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)piperidin-1-yl)metyl)-4-metyl-1H-indol-2-karbonitril;
5-((4-(1-(4-klorfenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl)piperidin-1-yl)metyl)-4-metyl-1H-indol-2-karbonitril;
1-(4-fluorfenyl)-3-(1-isopentylpiperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin;
1-(4-fluorfenyl)-3-(1-fenetylpiperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin;
5-(4-fluorfenyl)-7-(1-((tetrahydro-2H-pyran-4-yl)metyl)piperidin-4-yl)-5H-pyrrolo[3,2-d]pyrimidin;
5-((4-(5-(4-fluorfenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-4-metyl-1H-indol-2-karbonitril;
5-((4-(5-(4-fluorfenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-1H-benzo[d]imidazol-2(3H)-on;
7-(1-((1H-indol-6-yl)metyl)piperidin-4-yl)-5-(4-fluorfenyl)-SH-pyrrolo[3,2-d]pyrimidin;
7-(1-((1H-indol-5-yl)metyl)piperidin-4-yl)-5-(4-fluorfenyl)-SH-pyrrolo[3,2-d]pyrimidin;
5-((4-(5-(3-fluorfenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-4-metyl-1H-indol-2-karbonitril;
metyl-5-((4-(5-fenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-1H-indol-2-karbonitril;
4-metyl-5-((4-(5-fenyl-SH-pyrrolo[3,2-d]pyrimidin-7-yl)piperidin-1-yl)metyl)-1H-indol-2-karbonitril;
5-((4-(3-(4-fluorfenyl)-2-okso-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)piperidin-1-yl)metyl)-4-metyl-1H-indol-2-karbonitril;
eller et farmasøytisk akseptabelt salt derav.

15. Forbindelsen ifølge krav 1, som er 5-fluor-N-isopropyl-N-metyl-2-(3-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid, eller et farmasøytisk akseptabelt salt derav.

16. Farmasøytisk akseptabelt salt av forbindelsen ifølge krav 15, som er et mono-(2R,3S,4R,5S)-2,3,4,5-tetrahydroksyheksandisyresalt,
en krystallinsk form derav, hvori den krystallinske formen er karakterisert av et XRPD-mønster som har minst én, minst to, minst tre eller minst fire topper, i form av 2-theta, valgt fra ca. 7,2°, ca. 11,4°, ca. 12,4°, ca. 14,5°, ca. 15,7°, ca. 16,2°, ca. 17,6°, ca. 18,4°, ca. 18,8°, ca. 20,9°, ca. 21,6°, ca. 21,8°, ca. 23,9°, ca. 24,6°, ca. 24,8°, ca. 29,9°, ca. 28,0°, ca. 35,0° og ca. 37,3° eller
hvori den krystallinske formen av 5-fluor-N-isopropyl-N-metyl-2-(3-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-3-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)benzamid-mono-(2R,3S,4R,5S)-2,3,4,5-tetrahydroksyheksandionsyre (mucat) salt er karakterisert av et XRPD-mønster som har minst én, minst to, minst tre eller minst fire topper, i form av 2-theta, valgt fra ca. 7,2°, ca. 12,4°, ca. 17,6°, ca. 18,4°, ca. 20,9°, ca. 21,6°, ca. 21,8°, ca. 23,9°, ca. 24,6°, ca. 24,8° og ca. 29,9°.

17. Farmasøytisk sammensetning omfattende
(a) en forbindelse ifølge et hvilket som helst av kravene 1 til 15, eller et farmasøytisk akseptabelt salt derav, og minst én farmasøytisk akseptabel bærer; eller
(b) saltet eller den krystallinske formen ifølge krav 16, og minst én farmasøytisk akseptabel bærer.

18. Forbindelsen ifølge et hvilket som helst av kravene 1 til 15 eller et farmasøytisk akseptabelt salt derav, eller saltet eller den krystallinske formen ifølge krav 16, for anvendelse i en fremgangsmåte for å inhibere interaksjonen mellom menin og MLL omfattende å bringe meninet og MLL i kontakt med forbindelsen, saltet eller den krystallinske formen.

19. Forbindelsen ifølge et hvilket som helst av kravene 1 til 15 eller et farmasøytisk akseptabelt salt derav, eller saltet eller den krystallinske formen ifølge krav 16, for anvendelse i en fremgangsmåte for behandling av kreft hos en pasient omfattende administrering til pasienten av en terapeutisk effektiv mengde av forbindelsen, saltet eller den krystallinske formen.

20. Forbindelsen, saltet eller den krystallinske formen for anvendelse ifølge krav 19, hvori kreften er:

(a) en hematologisk kreft;

(b) leukemi;

(c) lymfom;

(d) blandet avstamningsleukemi (MLL), MLL-relatert leukemi, MLL-assosiert leukemi, MLL-positiv leukemi, MLL-indusert leukemi, omorganisert blandet avstamningsleukemi (MLL-r), leukemi assosiert med en MLL-omorganisering eller en omorganisering av *MLL*-genet, akutt leukemi, kronisk leukemi, indolent leukemi, lymfoblastisk leukemi, lymfatisk leukemi, myeloid leukemi, myelogen leukemi, barneleukemi, akutt lymfatisk leukemi (ALL), akutt myeloid leukemi (AML), akutt granulocytisk leukemi, akutt granulocytisk leukemi, kronisk lymfatisk leukemi (KLL), kronisk myelogen leukemi (KML), terapirelatert leukemi, myelodysplastisk syndrom (MDS), myeloproliferativ sykdom (MPD), myeloproliferativ neoplasi (MPN), plasmacelleneoplasme, multippelt myelom, myelodysplasi, kutant T-cellelymfom, lymfoid neoplasma, AIDS-relatert lymfom, tymom, tymisk karsinom, mycosis fungoides, Alibert-Bazin syndrom, granuloma fungoides, Sézary syndrom, hårcelleleukemi, T-celleprolymfocytisk leukemi (T-PLL), stor granulær lymfatisk leukemi, meningeal leukemi, leukemisk leptomeningitt, leukemisk meningitt, multippelt myelom, Hodgkins lymfom, non-Hodgkins lymfom (malignt lymfom), eller Waldenströms makroglobulinemi; eller

(e) abstrakt nukleofosmin (NPM1)-mutert akutt myeloid leukemi (dvs. $NPM1^{mut}$ akutt myeloid leukemi).

21. Forbindelsen ifølge et hvilket som helst av kravene 1 til 15 eller et farmasøytisk akseptabelt salt derav, eller saltet eller den krystallinske formen ifølge krav 16, for anvendelse i:

(a) en fremgangsmåte for behandling av insulinresistens, pre-diabetes, diabetes eller risiko for diabetes hos en pasient omfattende administrering til pasienten av en terapeutisk effektiv mengde av forbindelsen, saltet eller den krystallinske formen; eller

(b) en fremgangsmåte for behandling av hyperglykemi hos en pasient omfattede administrering til pasienten av en terapeutisk effektiv mengde av forbindelsen, saltet eller den krystallinske formen.